CD95/Fas-Ligation and resting NK or IL-2 activated NK (LAK) attack Limit NK-92 efficacy

Navarrete-Galvan, LT; Guglielmo, M; Amaya, JC; Merica, R; Smith-Gagen, J; Lombardi, VC; Hudig, D

JOURNAL OF IMMUNOLOGY, 2022; 208 (1):